Merriman Curhan Ford Reiterates a 'Buy' on Regeneron (REGN); Raising Target Range
REGN Hot Sheet
Rating Summary:9 Buy, 9 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 4 | Down: 4 | New: 8
Merriman Curhan Ford reiterates a 'Buy' rating on Regeneron (Nasdaq: REGN), raising target range to $34-35 from $29-31.
Merriman analyst says, "Regeneron is developing a proprietary set of “antibody-like” compounds called “traps” that can target signaling molecules with distinct implication in multiple diseases. In our view, Regeneron is an exciting biopharmaceutical development story based primarily on its first product on the market, late-stage product candidates and strong partners. The company has premier science being translated into clinically viable candidates and a strong management team. We believe Regeneron represents a core long-term biotech portfolio holding."
To see more analyst ratings on REGN Click Here.
Merriman analyst says, "Regeneron is developing a proprietary set of “antibody-like” compounds called “traps” that can target signaling molecules with distinct implication in multiple diseases. In our view, Regeneron is an exciting biopharmaceutical development story based primarily on its first product on the market, late-stage product candidates and strong partners. The company has premier science being translated into clinically viable candidates and a strong management team. We believe Regeneron represents a core long-term biotech portfolio holding."
To see more analyst ratings on REGN Click Here.
You May Also Be Interested In
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Merriman Curhan FordSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
